The origin of CD95-gene mutations in B-cell lymphoma

被引:58
作者
Müschen, M
Rajewsky, K
Krönke, M
Küppers, R
机构
[1] Univ Cologne, Inst Med Mikrobiol Immunol & Hyg, D-50935 Cologne, Germany
[2] Univ Cologne, Genet Inst, D-50931 Cologne, Germany
关键词
D O I
10.1016/S1471-4906(01)02115-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD95(Apo-1/Fas) is crucial for the negative selection of B cells within the germinal center (GC). Impairment of CD95-mediated apoptosis results in defective affinity maturation and the persistence of autoreactive B-cell clones. CD95 was defined recently as a tumor-suppressor gene and is silenced in many tumor entities. In contrast to other malignancies, in GC-derived B-cell lymphomas, inactivation of the CD95 gene is often a result of deleterious mutations. Such mutations occur also at a low frequency in normal GC, but not naive, B cells. We propose that CD95mutations in B-cell lymphomas originate from the GC reaction and are introduced most probably as targeting errors of the somatic hypermutation machinery, which bears - besides its physiological role - an inherent risk of malignant transformation and the persistence of autoreactive B-cell specificities.
引用
收藏
页码:75 / 80
页数:6
相关论文
共 47 条
[1]   Death pathway genes Fas (Apo-1/CD95) and Bik (Nbk) show no mutations in colorectal carcinomas [J].
Abdel-Rahman, WM ;
Arends, MJ ;
Wyllie, AH ;
Morris, RG ;
Ramadan, ME .
CELL DEATH AND DIFFERENTIATION, 1999, 6 (05) :387-388
[2]   Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia [J].
Beltinger, C ;
Böhler, T ;
Karawajew, L ;
Ludwig, WD ;
Schrappe, M ;
Debatin, KM .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) :722-728
[3]  
Beltinger C, 1998, BLOOD, V91, P3943
[4]   Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas [J].
Bertoni, F ;
Conconi, A ;
Luminari, S ;
Realini, C ;
Roggero, E ;
Baldini, L ;
Carobbio, S ;
Cavalli, F ;
Neri, A ;
Zucca, E .
LEUKEMIA, 2000, 14 (03) :446-448
[5]  
Bertoni F, 2000, INT J CANCER, V86, P450
[6]   Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions [J].
Davidson, WF ;
Giese, T ;
Fredrickson, TN .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (11) :1825-1838
[7]   DOMINANT INTERFERING FAS GENE-MUTATIONS IMPAIR APOPTOSIS IN A HUMAN AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME [J].
FISHER, GH ;
ROSENBERG, FJ ;
STRAUS, SE ;
DALE, JK ;
MIDDELTON, LA ;
LIN, AY ;
STROBER, W ;
LENARDO, MJ ;
PUCK, JM .
CELL, 1995, 81 (06) :935-946
[8]   Frequent occurrence of deletions and duplications during somatic hypermutation:: Implications for oncogene translocations and heavy chain disease [J].
Goossens, T ;
Klein, U ;
Küppers, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (05) :2463-2468
[9]  
Gronbaek K, 1998, BLOOD, V92, P3018
[10]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70